Costs of HIV+/AIDS at CD4+ Counts Disease Stages Based on Treatment Protocols
- 1 August 1996
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 12 (4) , 413-420
- https://doi.org/10.1097/00042560-199608010-00013
Abstract
Summary: We report treatment protocols for HIV+/AIDS patients by CD4+ counts (T-lymphocyte cells/mm3: ≥500, 499-200, 199-50, and +/AIDS. The treatment protocols, derived from the literature and an HIV+/AIDS Physician Panel, defined the resource use associated with antiretroviral therapy and opportunistic disease prophylaxis and treatment. Resource use costs were derived from the published literature, insurance databases, Medicare fee schedules, surveys, and the Physician Panel. At CD4+ counts, the rates of opportunistic diseases were derived from the Physician Panel experience; the mean occupancy times were derived from the literature. The sensitivity analysis indicated stability of the lifetime costs to variation in mean occupancy times, rates of opportunistic diseases, rates of adverse events (AE), and costs. The total annual costs (1995 dollars) of HIV+/AIDS patients ranged from $1,934 (≥500), $6,015 (200-499), and $9,031 (50-199), to $25,239 (Mycobacterium avium complex (MAC) ($20,153), Non-Hodgkin's lymphoma (NHL) ($22,329), wasting syndrome ($26,676), central nervous system (CNS) lymphoma ($27,333), Pneumocystis carinii pneumonia (PCP) [mild ($3,545), moderate ($4,889), and severe ($32,609)], Kaposi' sarcoma (KS) [mild/moderate ($5,902), and severe ($10,744)], and cytomegalovirus (CMV) retinitis ($100,337). The projected lifetime costs of HIV+/AIDS are $94,726 (annual costs $7,645). Our lower lifetime costs as compared with recent estimates may be due to including resources only for HIV+/AIDS-related treatment and not for non-HIV+/AIDS conditions, as well as reduced resource use resulting from more efficient diagnostic and therapeutic techniques and earlier prophylaxis provided by experienced HIV+/AIDS physicians. Nonetheless, our estimates are consistent with decreasing costs of HIV+/AIDS due to a reduction in the average length of stay and frequency of hospitalizations as well as to replacement of inpatient care by outpatient services.Keywords
This publication has 21 references indexed in Scilit:
- Clinical and Economic Aspects of Prophylaxis and Treatment of Pneumocystis carinii PneumoniaPharmacoEconomics, 1995
- The lifetime cost of treating a person with HIVJAMA, 1993
- Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care systemArchives of internal medicine (1960), 1993
- An Exploratory Analysis of Survival with AIDS Using a Nonparametric Tree-Structured ApproachEpidemiology, 1992
- The effect of changing the definition of AIDS on the modeling of AIDSPublished by American Medical Association (AMA) ,1992
- The Effects on Survival of Early Treatment of Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- The Pharmacoeconomics of HIV DiseasePharmacoEconomics, 1992
- Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal MeningitisNew England Journal of Medicine, 1992
- Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumoniaPublished by American Medical Association (AMA) ,1991
- Survival trends for patients with AIDSJAMA, 1990